Table 1.

Atopic conditions and risk of NHL in case-control studies

Study author, year, and location*Type of case-control studyCases (n)Odds ratio and 95% CI
Eczema
    Cartwright (1988), United Kingdom (1)Hospital based4371.6 (1.1–2.4)
    Bernstein (1992), USA (2)Population based6190.6 (0.4–1.0)
    Doody (1992), USA (3)Population based1001.9 (0.6–5.8)
    Vineis (2000), Italy (4)Population based1,3881.2 (0.9–1.6)
    Fabbro-Peray (2001), France (5)Population based4450.5 (0.3–0.7)
    Zhang (2004), USA women (6)Population based6011.3 (0.9–1.9)
    Becker (2005), Germany (7)Population based5540.7 (0.5–1.0)
    Grulich (2005), Australia (8)Population based7040.8 (0.6–1.1)
Hayfever
    Doody (1992), USA (3)Population based1000.5 (0.2–1.2)
    Bernstein (1992), USA (2)Population based6191.0 (M), 1.0 (F)
    Vineis (2000), Italy (4)Population based1,3880.7 (0.5–1.0)
    Zhang (2004), USA women (6)Population based6011.0 (0.8–1.4)
    Becker (2005), Germany (7)Population based5540.6 (0.4–0.9)
    Grulich (2005), Australia (8)Population based7040.7 (0.5–0.8)
    Bracci (in press), USA (9)Population based1,3040.7 (0.6–0.8)
Asthma
    Cartwright (1988), United Kingdom (1)Hospital based4370.8 (0.4–1.5)
    Holly (1999), USA (10)Population based701 MM 0.9 (0.6–1.2)
580 FF 0.8 (0.5–1.2)
    Tavani (2000), Italy (11)Hospital based4290.8 (0.5–1.4)
    Fabbro-Peray (2001), France (5)Population based4450.8 (0.5–1.3)
    Zhang (2004), USA women (6)Population based6011.0 (0.7–1.4)
    Becker (2005), Germany (7)Population based5540.4 (0.2–0.8)
    Grulich (2005), Australia (8)Population based7040.7 (0.5–0.8)
    Lee (2006), US (12)Population based6680.9 (0.6–1.4)
  • * Numbers are references added to the supplementary data.